Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. [electronic resource]
Producer: 20130916Description: 2611-9 p. digitalISSN:- 1097-0142
- Aged
- Aged, 80 and over
- Antimetabolites, Antineoplastic -- therapeutic use
- Antineoplastic Agents -- administration & dosage
- Aurora Kinase B
- Aurora Kinases
- Cytarabine -- administration & dosage
- Drug Administration Schedule
- Female
- Humans
- Kaplan-Meier Estimate
- Leukemia, Myeloid, Acute -- drug therapy
- Male
- Neutropenia -- chemically induced
- Organophosphates -- administration & dosage
- Protein Serine-Threonine Kinases -- antagonists & inhibitors
- Quinazolines -- administration & dosage
- Stomatitis -- chemically induced
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.